SCHEMBL926285

SCHEMBL926285

CC(=O)Nc1ccc2oc(-c3ccc(O)cc3)c(O)c(=O)c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.67
MEN1 O00255 7/20 0.67
CYP3A4 P08684 7/20 0.67
KMT2A Q03164 7/20 0.67
KDM4E B2RXH2 6/20 0.67
HSD17B10 Q99714 5/20 0.67
CYP2C9 P11712 3/20 0.67
ALDH1A1 P00352 5/20 0.56
TP53 P04637 5/20 0.56
HPGD P15428 3/20 0.56
ALOX15 P16050 3/20 0.56
CASP1 P29466 3/20 0.56
CASP7 P55210 3/20 0.56
MAPK1 P28482 2/20 0.56
FTO Q9C0B1 2/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 2/20 0.56
USP2 O75604 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CYP1A2 P05177 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17786621 0.90 ACHE (0.55) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL5126244 0.90 KDM4E (0.64) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL17786624 0.89 MAPT (0.52) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL925783 0.88 CSNK2A2 (0.67) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL7652860 0.88 MEN1 (0.60) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL928184 0.87 MAPT (0.50) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL17786494 0.84 MAPT (0.69) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL12963109 0.84 MAPT (0.58) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL17786540 0.83 CSNK2A2 (0.55) MAPTMEN1CYP3A4KMT2AKDM4E
SCHEMBL1082928 0.83 MAPT (0.53) MAPTMEN1CYP3A4KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 US disclosed
EP-2268628-B1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM SPA (IT) 2012-05-16 EP disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 US disclosed
EP-2268628-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN Rottapharm S.p.A. (IT) 2011-01-05 EP disclosed
WO-2009109230-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN NAT1, AADAC, OPRL1 MAPT 4791/4885MEN1 3571/4885CYP3A4 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.